Core Insights - Iradimed Corporation reported record revenue of $21.2 million for Q3 2025, marking a 16% increase year-over-year, and maintained a strong gross margin of 78% [2][6][8] - The company is set to begin limited commercial shipments of its next-generation 3870 MRI-compatible IV infusion pump in December 2025, with full commercialization expected in Q1 2026 [3][4] - For Q4 2025, the company anticipates revenue between $21.4 million and $22.4 million, and has raised its full-year revenue guidance to $82.5 million to $83.5 million [4][16] Financial Performance - For the three months ended September 30, 2025, the company reported net income of $5.6 million, an increase of 10% from $5.0 million in Q3 2024, translating to diluted earnings per share of $0.43, up 8% from $0.40 [6][8] - Non-GAAP net income for Q3 2025 was $6.1 million, a 10% increase from $5.5 million in the same period of 2024, with non-GAAP diluted earnings per share at $0.47, up 9% [7][10] - For the nine months ended September 30, 2025, revenue reached $61.1 million, a 13% increase from $53.9 million in the same period of 2024, with net income also increasing by 13% to $16.0 million [9][10] Operational Highlights - The company completed the construction of its new facility in Orlando, Florida, with total costs amounting to approximately $13.3 million, and the facility is now fully operational [15] - The backlog for the company's pump and monitor products is at an all-time high, indicating strong demand [2][3] - Domestic sales accounted for 85% of total revenue for both Q3 and the nine months ended September 30, 2025, compared to 83% and 82% respectively in the prior year [11][12] Dividend Information - The board of directors declared a regular quarterly cash dividend of $0.17 per share, payable on November 25, 2025, to stockholders of record as of November 14, 2025 [5][8]

Core Insights - Iradimed Corporation reported record revenue of $20.4 million for Q2 2025, marking a 14% increase year-over-year, and a GAAP diluted EPS of $0.45, up 18% year-over-year [3][9][10] - The company raised its full-year 2025 revenue guidance to a range of $80.0 million to $82.5 million, and GAAP diluted EPS guidance to $1.60 to $1.70 [4][17] - A quarterly cash dividend of $0.17 per share was declared, payable on August 28, 2025 [5][9] Financial Performance - For Q2 2025, net income was reported at $5.8 million, an 18% increase from $4.9 million in Q2 2024, translating to $0.45 per diluted share [6][10] - Non-GAAP net income for Q2 2025 was $6.4 million, a 19% increase from $5.4 million in Q2 2024, with non-GAAP diluted EPS at $0.49, up 17% [7][11] - For the first half of 2025, total revenue reached $39.9 million, a 12% increase from $35.5 million in the same period of 2024, with net income of $10.5 million, up 16% [10][11] Operational Highlights - The gross profit margin for Q2 2025 was 78%, consistent with the same period in 2024, driven by increased overhead absorption [3][12] - Domestic sales accounted for 89% of total revenue in Q2 2025, compared to 86% in Q2 2024 [12] - The company completed the construction of a new facility in Orlando, Florida, with total construction costs of approximately $12.6 million [16] Future Outlook - For Q3 2025, the company expects revenue between $20.5 million and $20.9 million, with GAAP diluted EPS guidance of $0.41 to $0.45 [4][17] - The anticipated commercialization of a next-generation MRI-compatible IV infusion pump is expected to drive sustained growth starting late 2025 [3][4]

Core Insights - Iradimed Corporation reported record revenue of $19.5 million for Q1 2025, an 11% increase year-over-year, and a 16% rise in diluted EPS [3][6][8] - The company declared a regular quarterly cash dividend of $0.17 per share, reaffirming its commitment to shareholder value [5][3] - Financial guidance for Q2 2025 includes expected revenue of $19.7 million to $19.9 million and GAAP diluted EPS of $0.37 to $0.40 [4][11] Financial Performance - For the three months ended March 31, 2025, revenue was $19.5 million, up from $17.6 million in Q1 2024, marking an 11% increase [6][8] - Net income for the same period was $4.7 million, a 15% increase from $4.1 million in Q1 2024, resulting in diluted EPS of $0.37, up 16% [6][31] - Non-GAAP net income was reported at $5.3 million, excluding stock compensation expenses, reflecting a 15% increase year-over-year [7][31] Revenue Breakdown - Revenue from MRI compatible IV infusion pump systems was $5.999 million, and from patient vital signs monitoring systems was $6.545 million, contributing to a total devices revenue of $12.962 million [9] - Domestic sales accounted for 82% of total revenue, an increase from 76% in the same period of 2024 [9] Cash Flow and Expenditures - Cash flow from operations for Q1 2025 was $4.3 million, a 10% increase from $3.9 million in Q1 2024 [10] - The company anticipates spending approximately $3.0 million on its new manufacturing facility in Orlando, Florida, expected to be completed in July 2025 [10] Future Guidance - For Q2 2025, the company expects revenue between $19.7 million and $19.9 million, with GAAP diluted EPS projected at $0.37 to $0.40 [4][11] - Full-year 2025 guidance remains unchanged, with expected revenue of $78.0 million to $82.0 million and GAAP diluted EPS of $1.55 to $1.65 [4][11]